# Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas

> **NCT05389423** · PHASE1 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 25 (estimated)

## Conditions studied

- Diffuse Large Cell Lymphoma
- Non-Hodgkin Lymphoma
- Burkitt Lymphoma
- Plasmablastic Lymphoma
- B-Cell Neoplasm

## Interventions

- **DRUG:** Vincristine
- **DRUG:** Prednisone
- **DRUG:** Doxorubicin
- **DRUG:** Etoposide
- **DRUG:** Pomalidomide
- **DRUG:** Cyclophosphamide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT05389423
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-06-27
- **Primary completion:** 2028-06-01
- **Final completion:** 2032-06-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-04-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05389423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05389423, "Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05389423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*